New Feature: Flag stocks with color on Portolios & Screener

Ovid Therapeutics Inc.

Contributing Author

Recent Articles by Ovid Therapeutics Inc.

Jul-08	Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development OVID GlobeNewswire
Jun-04	Ovid Therapeutics to Participate in Upcoming Investor Conferences OVID GlobeNewswire
Jun-03	Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors OVID GlobeNewswire
May-12	Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results OVID GlobeNewswire
Apr-08	Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 OVID GlobeNewswire
Mar-18	Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results OVID +14.43% GlobeNewswire
Mar-18	Ovid Therapeutics Announces Pricing of $60 Million Private Placement OVID +14.43% GlobeNewswire
Feb-25	Ovid Therapeutics to Participate in Upcoming Investor Conferences OVID +7.28% GlobeNewswire
Dec-18	Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) OVID -9.46% GlobeNewswire
Dec-02	Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer OVID -13.33% GlobeNewswire
Nov-12	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results OVID GlobeNewswire
Oct-03	Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds OVID +12.20% GlobeNewswire
Oct-03	Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile OVID +12.20% GlobeNewswire
Aug-13	Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results OVID +56.86% GlobeNewswire
Jul-23	Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference OVID GlobeNewswire
Jun-25	Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties OVID GlobeNewswire
Jun-05	Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 OVID GlobeNewswire
May-13	Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results OVID -5.30% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)